TABLE 1.
Demographic characteristics of the patients
| Characteristics | Total (n = 45) | Surgery (n = 26) | CRT + surgery (n = 19) | p‐value |
|---|---|---|---|---|
| Age (years) | 55.00 (47.00–60.00) | 53.00 (46.25–59.25) | 56.00 (48.50–60.00) | 0.578 |
| Gender | 0.167 | |||
| Male | 22 (48.89%) | 15 (57.69%) | 7 (36.84%) | |
| Female | 23 (51.11%) | 11 (42.31%) | 12 (63.16%) | |
| BMI (kg/m2) | 24.15 ± 3.22 | 24.85 ± 2.42 | 23.21 ± 3.94 | 0.091 |
| FEV1 (%) | 86.33 ± 7.11 | 87.13 ± 6.75 | 85.24 ± 7.63 | 0.385 |
| %FEV1 | 0.193 | |||
| <80 | 6 (13.33%) | 2 (7.69%) | 4 (21.05%) | |
| ≥80 | 39 (86.67%) | 24 (92.31%) | 15 (78.95%) | |
| Smoke | 0.363 | |||
| Never | 35 (77.78%) | 21 (80.77%) | 14 (73.68%) | |
| Current smokers | 4 (8.89%) | 3 (11.54%) | 1 (5.26%) | |
| Abstained for at least one year | 6 (13.33%) | 2 (7.69%) | 4 (21.05%) | |
| ASA grade | 0.091 | |||
| 1 | 27 (60.00%) | 13 (50.00%) | 14 (73.68%) | |
| 2 | 15 (33.33%) | 12 (46.15%) | 3 (15.79%) | |
| 3 | 3 (6.67%) | 1 (3.85%) | 2 (10.53%) | |
| Thymoma‐related syndrome | 0.290 | |||
| None | 33 (73.33%) | 18 (69.23%) | 15 (78.95%) | |
| Ocular myasthenia gravis | 6 (13.33%) | 5 (19.23%) | 1 (5.26%) | |
| Generalized myasthenia gravis | 4 (8.89%) | 1 (3.85%) | 3 (15.79%) | |
| Hypogammaglobulinemia (Good's syndrome) | 1 (2.22%) | 1 (3.85%) | 0 (0.00%) | |
| Pure red cell aplasia (PRCA) | 1 (2.22%) | 1 (3.85%) | 0 (0.00%) | |
| Duration of myasthenia (months) | 2.00 (0.00–6.00) | 3.00 (1.00–10.50) | 2.00 (0.00–6.00) | 0.648 |
| Tumor size based on preoperative radiological examination (cm) | 0.394 | |||
| <5 | 9 (20.00%) | 7 (26.92%) | 2 (10.53%) | |
| 5–10 | 25 (55.56%) | 13 (50.00%) | 12 (63.16%) | |
| >10 | 11 (24.44%) | 6 (23.08%) | 5 (26.32%) | |
| Main tumor location | 0.154 | |||
| Midline | 24 (53.33%) | 13 (50.00%) | 11 (57.89%) | |
| Left | 8 (17.78%) | 7 (26.92%) | 1 (5.26%) | |
| Right | 13 (28.89%) | 6 (23.08%) | 7 (36.84%) | |
| Preoperative Masaoka stage | 0.974 | |||
| IIIB | 24 (53.33%) | 14 (53.85%) | 10 (52.63%) | |
| IVA | 19 (42.22%) | 11 (42.31%) | 8 (42.11%) | |
| IVB | 2 (4.44%) | 1 (3.85%) | 1 (5.26%) | |
| Preoperative TNM stage | 0.367 | |||
| IIIA | 15 (33.33%) | 6 (23.08%) | 9 (47.37%) | |
| IIIB | 6 (13.33%) | 4 (15.38%) | 2 (10.53%) | |
| IVA | 22 (48.89%) | 15 (57.69%) | 7 (36.84%) | |
| IVB | 2 (4.44%) | 1 (3.85%) | 1 (5.26%) | |
| Site of tumor infiltration based on preoperative radiological examination | 0.250 | |||
| SVC + lung | 20 (44.44%) | 9 (34.62%) | 11 (57.89%) | |
| SVC + pulmonary artery trunk | 4 (8.89%) | 2 (7.69%) | 2 (10.53%) | |
| SVC + pericardium | 5 (11.11%) | 5 (19.23%) | 0 (0.00%) | |
| SVC + pleural dissemination | 14 (31.11%) | 9 (34.62%) | 5 (26.32%) | |
| SVC + pulmonary metastasis | 2 (4.44%) | 1 (3.85%) | 1 (5.26%) | |
| Radiation dose (Gy) | ‐ | |||
| ≤46 | ‐ | ‐ | 10 (22.22%) | |
| >46 | ‐ | ‐ | 2 (4.44%) | |
| Chemotherapy regimens | ‐ | |||
| cisplatin + doxorubicin + cyclophosphamide | 9 (20.00%) | |||
| cisplatin + epirubicin + ifosfamide | 5 (11.11%) | |||
| carboplatin + epirubicin + cyclophosphamide | 4 (8.89%) | |||
| carboplatin + epirubicin + etoposide | 1 (2.22%) |
Categoric data are expressed as number (%) and continuous data as mean ± SD or median (interquartile range). Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; FEV1, forced expiratory volume in 1 second; SVC, superior vena cava.